BG60256B2 - Рекомбинантен метод за получаване на лимфотоксин - Google Patents

Рекомбинантен метод за получаване на лимфотоксин Download PDF

Info

Publication number
BG60256B2
BG60256B2 BG70460A BG7046085A BG60256B2 BG 60256 B2 BG60256 B2 BG 60256B2 BG 70460 A BG70460 A BG 70460A BG 7046085 A BG7046085 A BG 7046085A BG 60256 B2 BG60256 B2 BG 60256B2
Authority
BG
Bulgaria
Prior art keywords
lymphotoxin
dna
sequence
amino acid
nucleic acid
Prior art date
Application number
BG70460A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG60256B1 (bg
Inventor
Bharat Aggarwal
Timothy BRINGMAN
Patrick Gray
Glenn Nedwin
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502 external-priority patent/US4959457A/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BG60256B1 publication Critical patent/BG60256B1/bg
Publication of BG60256B2 publication Critical patent/BG60256B2/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • C07K16/242Lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • C07K14/5255Lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG70460A 1984-05-31 1985-05-30 Рекомбинантен метод за получаване на лимфотоксин BG60256B2 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61650384A 1984-05-31 1984-05-31
US06/616,502 US4959457A (en) 1984-05-31 1984-05-31 Anti-lymphotoxin
US73231285A 1985-05-09 1985-05-09

Publications (2)

Publication Number Publication Date
BG60256B1 BG60256B1 (bg) 1994-03-24
BG60256B2 true BG60256B2 (bg) 1994-03-24

Family

ID=27417179

Family Applications (1)

Application Number Title Priority Date Filing Date
BG70460A BG60256B2 (bg) 1984-05-31 1985-05-30 Рекомбинантен метод за получаване на лимфотоксин

Country Status (23)

Country Link
EP (2) EP0509553B1 (sk)
JP (3) JP2521703B2 (sk)
AR (1) AR245219A1 (sk)
AT (2) ATE95243T1 (sk)
AU (1) AU599303B2 (sk)
BG (1) BG60256B2 (sk)
CA (1) CA1340641C (sk)
CZ (1) CZ283148B6 (sk)
DE (2) DE3587597T2 (sk)
DK (1) DK171531B1 (sk)
ES (1) ES8802182A1 (sk)
FI (1) FI93025C (sk)
GR (1) GR851317B (sk)
HU (1) HU204085B (sk)
IE (1) IE63487B1 (sk)
IL (1) IL75318A (sk)
NO (1) NO179075C (sk)
NZ (1) NZ212207A (sk)
PL (1) PL155410B1 (sk)
PT (1) PT80573B (sk)
RO (1) RO100383A2 (sk)
SK (1) SK393085A3 (sk)
YU (1) YU47735B (sk)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR860001471B1 (ko) 1980-04-03 1986-09-26 비오겐 엔. 브이 인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
ATE73856T1 (de) * 1984-12-21 1992-04-15 Biogen Inc Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
JPS62111928A (ja) * 1985-10-15 1987-05-22 Kanegafuchi Chem Ind Co Ltd 新規リンホトキシン
JPS62195285A (ja) * 1986-02-19 1987-08-28 Kanegafuchi Chem Ind Co Ltd リンホトキシン発現ベクタ−及びそれを用いるリンホトキシンの製造方法
JP2548204B2 (ja) * 1987-06-27 1996-10-30 電気化学工業株式会社 新生理活性ポリペプチド
EP0230781B1 (en) * 1985-12-24 1992-07-22 Denki Kagaku Kogyo Kabushiki Kaisha Lymphotoxin gene, method for its production, and lymphotoxin
US5403725A (en) * 1985-12-24 1995-04-04 Denki Kagaku Kogyo Kabushiki Kaisha Method for production of lymphotoxin (TNFB) in cell line A-C5-8
EP0230574A3 (en) * 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
JPS62181298A (ja) * 1986-02-05 1987-08-08 Kyowa Hakko Kogyo Co Ltd ヒトリンホトキシンポリペプチド誘導体
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
JPS63105680A (ja) * 1986-10-22 1988-05-10 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシン発現ベクタ−、該発現ベクタ−による形質転換細胞および該細胞を用いるリンホトキシンの製造方法
US5175268A (en) * 1986-12-24 1992-12-29 Takeda Chemical Industries, Ltd. DNA encoding recombinant human lymphotoxin
JP2636862B2 (ja) * 1986-12-24 1997-07-30 武田薬品工業株式会社 組み換え型ヒトリンホトキシン
FI884798A (fi) * 1987-10-28 1989-04-29 Eisai Co Ltd Rekombinantlymfotoxin.
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217326B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene encoding human tumour necrosis factor beta.
EP0338497A3 (en) * 1988-04-22 1990-05-16 Takeda Chemical Industries, Ltd. Bispecific hybrid monoclonal antibody
JPH023698A (ja) * 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
CA2001756A1 (en) * 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
JPH03106821A (ja) * 1989-09-20 1991-05-07 Denki Kagaku Kogyo Kk 抗腫瘍剤
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
DE69622157T2 (de) * 1995-01-23 2003-03-13 Xenotech Inc., Fremont Zusammensetzung zur verhinderung von osteolyse und metastasen
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
WO1999036535A1 (en) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
EP1572116A4 (en) * 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
AU2004252171B2 (en) 2003-06-27 2011-04-21 Biogen Ma Inc. Modified binding molecules comprising connecting peptides
US20050266004A1 (en) * 2003-12-08 2005-12-01 Jill Giles-Komar Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP5298021B2 (ja) * 2006-10-12 2013-09-25 ジェネンテック, インコーポレイテッド リンホトキシン−αに対する抗体
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
BR112016024841A2 (pt) * 2014-04-25 2017-10-24 Naurex Inc composições estáveis de peptídeos neuroativos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59007A (en) * 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
ZA834976B (en) * 1982-07-30 1984-08-29 Genentech Inc Human lymphotoxin
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
EP0135797A3 (de) * 1983-08-30 1987-11-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA
DE3331108A1 (de) * 1983-08-30 1985-05-02 Boehringer Ingelheim International GmbH, 6507 Ingelheim Verfahren zur herstellung von lymphotoxin und von lymphotoxin-mrna
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production

Also Published As

Publication number Publication date
DE3588225D1 (de) 2000-09-14
PT80573A (en) 1985-06-01
EP0164965A3 (en) 1988-04-06
DE3588225T2 (de) 2001-04-05
RO100383A2 (ro) 1991-10-17
YU47735B (sh) 1996-01-08
IL75318A (en) 1994-08-26
EP0164965A2 (en) 1985-12-18
ATE195323T1 (de) 2000-08-15
NO179075C (no) 1996-07-31
SK278333B6 (en) 1996-11-06
PT80573B (pt) 1987-08-19
IL75318A0 (en) 1985-09-29
AU4320385A (en) 1985-12-05
BG60256B1 (bg) 1994-03-24
NO852173L (no) 1985-12-02
JPH07291995A (ja) 1995-11-07
CA1340641C (en) 1999-07-13
FI93025C (fi) 1995-02-10
FI93025B (fi) 1994-10-31
AR245219A1 (es) 1993-12-30
JPH07250692A (ja) 1995-10-03
DE3587597D1 (de) 1993-11-04
SK393085A3 (en) 1996-11-06
IE851321L (en) 1985-11-30
NO179075B (no) 1996-04-22
RO100383B1 (ro) 1991-03-01
CZ393085A3 (en) 1997-07-16
IE930589L (en) 1985-11-30
CZ283148B6 (cs) 1998-01-14
DK241385A (da) 1985-12-01
FI852143A0 (fi) 1985-05-29
ES543695A0 (es) 1988-04-16
JP2804237B2 (ja) 1998-09-24
JPS6156197A (ja) 1986-03-20
DK241385D0 (da) 1985-05-30
HUT37814A (en) 1986-02-28
EP0509553A1 (en) 1992-10-21
YU91985A (en) 1988-12-31
DE3587597T2 (de) 1994-06-01
FI852143L (fi) 1985-12-01
EP0509553B1 (en) 2000-08-09
AU599303B2 (en) 1990-07-19
ATE95243T1 (de) 1993-10-15
NZ212207A (en) 1991-07-26
EP0164965B1 (en) 1993-09-29
IE63487B1 (en) 1995-05-03
PL253739A1 (en) 1986-03-11
PL155410B1 (en) 1991-11-29
ES8802182A1 (es) 1988-04-16
DK171531B1 (da) 1996-12-23
HU204085B (en) 1991-11-28
GR851317B (sk) 1985-11-25
JP2521703B2 (ja) 1996-08-07

Similar Documents

Publication Publication Date Title
BG60256B2 (bg) Рекомбинантен метод за получаване на лимфотоксин
JP2614989B2 (ja) 腫瘍壊死因子含有組成物
US4650674A (en) Synergistic cytotoxic composition
US7964712B2 (en) Chimeric nucleic acids encoding polypeptides comprising TNF alpha, CD70 and FAS ligand domains
JPH08507201A (ja) リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
EP0499161A2 (en) GM-CSF inhibiting antibodies
US5683688A (en) Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US6686455B1 (en) Tumor necrosis factor
DK172382B1 (da) Rekombinante lymphotoxinderivater
NZ226980A (en) Lymphotoxin-neutralising antibody and its use in separating out lymphotoxin from a composition
IL104297A (en) Lymphotoxin Nucleic acid encoding vectors containing the nucleic acid and cells converted by them Methods for obtaining lymphotoxin
SI8511132A (sl) Faktor nekroze tumorja